Trial Profile
A Phase II Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Celecoxib (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms ADAPT
- 01 May 2017 Status changed from suspended to discontinued as Funding ended.
- 25 Mar 2016 Status changed from recruiting to suspended, according to ClinicalTrials.gov record.
- 31 May 2014 The study protocol presented at 50th Annual Meeting of the American Society of Clinical Oncology.